Optimizing biologically targeted clinical trials for neurofibromatosis
- 21 February 2013
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Opinion on Investigational Drugs
- Vol. 22 (4), 443-462
- https://doi.org/10.1517/13543784.2013.772979
Abstract
Introduction: The neurofibromatoses (neurofibromatosis type 1, NF1 and neurofibromatosis type 2, NF2) comprise the most common inherited conditions in which affected children and adults develop tumors of the central and peripheral nervous system. In this review, the authors discuss how the establishment of the Neurofibromatosis Clinical Trials Consortium (NFCTC) has positively impacted on the design and execution of treatment studies for individuals with NF1 and NF2. Areas covered: Using an extensive PUBMED search in collaboration with select NFCTC members expert in distinct NF topics, the authors discuss the clinical features of NF1 and NF2, the molecular biology of the NF1 and NF2 genes, the development and application of clinically relevant Nf1 and Nf2 genetically engineered mouse models and the formation of the NFCTC to enable efficient clinical trial design and execution. Expert opinion: The NFCTC has resulted in a more seamless integration of mouse preclinical and human clinical trials efforts. Leveraging emerging enabling resources, current research is focused on identifying subtypes of tumors in NF1 and NF2 to deliver the most active compounds to the patients most likely to respond to the targeted therapy.Keywords
This publication has 118 references indexed in Scilit:
- Scram1 is a modifier of spinal cord resistance for astrocytoma on mouse Chr 5Mammalian Genome, 2011
- Binary Regulation of Hippo Pathway by Merlin/NF2, Kibra, Lgl, and Melted Specifies and Maintains Postmitotic Neuronal FateDevelopmental Cell, 2011
- An Integrated In Vitro and In Vivo High-Throughput Screen Identifies Treatment Leads for EpendymomaCancer Cell, 2011
- Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine modelBone, 2011
- Cell of Origin and Microenvironment Contribution for NF1-Associated Dermal NeurofibromasCell Stem Cell, 2009
- Neurofibromin Regulation of ERK Signaling Modulates GABA Release and LearningCell, 2008
- Nf1-Dependent Tumors Require a Microenvironment Containing Nf1+/−- and c-kit-Dependent Bone MarrowCell, 2008
- How does the Schwann cell lineage form tumors in NF1?Glia, 2008
- Plexiform and Dermal Neurofibromas and Pigmentation Are Caused by Nf1 Loss in Desert Hedgehog-Expressing CellsCancer Cell, 2008
- Bone Mineral Density in Children and Adolescents with Neurofibromatosis Type 1The Journal of Pediatrics, 2007